Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,135,672
  • Shares Outstanding, K 699,252
  • Annual Sales, $ 13,003 M
  • Annual Income, $ 2,940 M
  • 36-Month Beta 1.44
  • Price/Sales 4.43
  • Price/Cash Flow 11.36
  • Price/Book 12.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 2.12
  • Number of Estimates 2
  • High Estimate 2.22
  • Low Estimate 2.02
  • Prior Year 1.87
  • Growth Rate Est. (year over year) +13.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.59 +47.64%
on 12/26/18
88.80 -2.59%
on 01/16/19
+25.58 (+41.99%)
since 12/21/18
3-Month
58.59 +47.64%
on 12/26/18
88.80 -2.59%
on 01/16/19
+6.73 (+8.44%)
since 10/23/18
52-Week
58.59 +47.64%
on 12/26/18
106.67 -18.91%
on 01/26/18
-18.05 (-17.26%)
since 01/23/18

Most Recent Stories

More News
Top Research Reports for Amazon, Verizon & AbbVie

Top Research Reports for Amazon, Verizon & AbbVie

CELG : 86.50 (+0.58%)
VZ : 57.76 (+1.35%)
LOW : 91.83 (+0.29%)
ABBV : 88.45 (-0.24%)
AMZN : 1,640.02 (+0.48%)
CB : 132.06 (+0.69%)
5 Best Biotech Bets Likely to Outperform Estimates in Q4

Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

CELG : 86.50 (+0.58%)
BLUE : 119.73 (-4.28%)
LLY : 118.79 (+1.45%)
ALNY : 80.01 (-0.81%)
LOXO : 233.70 (-0.03%)
REGN : 401.21 (-0.87%)
AMGN : 201.56 (-0.21%)
BMY : 49.96 (+0.48%)
CELG or VRTX: Which Is the Better Value Stock Right Now?

CELG vs. VRTX: Which Stock Is the Better Value Option?

CELG : 86.50 (+0.58%)
VRTX : 189.89 (-2.06%)
Fighting Cancer at the Root: VeraStem and Propanc Biopharma

TORONTO, ON / ACCESSWIRE / January 23, 2019 / The Wealthy Venture Capitalist (or "WVC"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known...

CELG : 86.50 (+0.58%)
OMED : 0.73 (-2.67%)
PPCB : 0.0153 (unch)
BAYN : 0.0100 (-32.43%)
BLCM : 3.09 (-4.33%)
INO : 4.78 (-4.40%)
VSTM : 3.45 (+4.86%)
CLLS : 15.69 (-1.20%)
Celgene Corp Set to Possibly Rebound After Yesterday's Selloff of 1.36%

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $84.63 to a high of $86.27. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $85.86...

CELG : 86.50 (+0.58%)
Can Celgene (CELG) Keep the Earnings Surprise Streak Alive?

Celgene (CELG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CELG : 86.50 (+0.58%)
What's in Store for Bristol-Myers (BMY) in Q4 Earnings?

Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.

CELG : 86.50 (+0.58%)
ABBV : 88.45 (-0.24%)
AMGN : 201.56 (-0.21%)
BMY : 49.96 (+0.48%)
Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?

While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.

CELG : 86.50 (+0.58%)
RHHBY : 32.4800 (+0.85%)
AMGN : 201.56 (-0.21%)
BIIB : 337.22 (-0.51%)
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

--- Kyn to receive $80 million upfront payment and an equity investment by Celgene with potential clinical, regulatory and commercial milestone payments, plus additional royalties on net sales from licensed...

CELG : 86.50 (+0.58%)
CELGZ : 0.95 (+2.15%)
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings

--Collaboration represents Obsidian's first major partnership and further expands Celgene's capabilities in cellular immunotherapy

CELG : 86.50 (+0.58%)
CELGZ : 0.95 (+2.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CELG with:

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

2nd Resistance Point 87.56
1st Resistance Point 87.03
Last Price 86.50
1st Support Level 85.88
2nd Support Level 85.26

See More

52-Week High 106.67
Fibonacci 61.8% 88.30
Last Price 86.50
Fibonacci 50% 82.63
Fibonacci 38.2% 76.96
52-Week Low 58.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar